<DOC>
	<DOCNO>NCT00839176</DOCNO>
	<brief_summary>The primary objective Phase IIa trial determine effective dose treatment period upcoming RX-10100 Phase IIb trial subject major depression disorder ( MDD ) . The secondary objective trial evaluate safety quality life subject MDD receive RX-10100 treatment .</brief_summary>
	<brief_title>Efficacy Study RX-10100 Treat Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Males females 18 65 year old Diagnosis MDD use DSMIV criterion Have score 20 HAMD17 Have score 4 CGIS Written inform consent obtain Have negative serum ( PHCG ) pregnancy test screening ( woman ) Female subject must meet one follow criterion : ( ) Be surgically sterile ( b ) Agree , sexually active use oral contraceptive , double barrier contraception ( E.g. , condom spermicide ) , intrauterine device , method approve sponsor . Have BMI &gt; 40 &lt; 18 Unstable angina pectoris History myocardial infarction , stroke , lifethreatening arrhythmia within prior 6 month Uncontrolled atrial fibrillation/flutter screen Severe chronic acute liver disease ; history moderate severe hepatic impairment Clinically significant chronic hematological disease may lead priapism , sickle cell anemia leukemia Bleeding disorder Resting hypotension hypertension History malignancy ( cancer ) within past 5 year ( squamous basal cell skin cancer ) NYHA Class III IV heart failure Substance abuse/dependence within past 6 month Significant suicidal ideation base CSSRS Other current nondepressive Axis I disorder Depressive episode duration le 1 month great 9 month Bipolar disorder Dysthmic disorder Borderline personality disorder Psychotic disorder/current psychotic feature Any abnormal finding screen ECG judge clinically significant Investigator Any medical condition stabilize anticipated require hospitalization within 6 month , opinion Investigator Any history cholestatic jaundice liver cirrhosis Hyper hypothyroidism unless subject receive stable dose thyroid medication least 3 month prior screen visit Women , breastfeeding , lactate within 3 month prior screen Concurrent psychotherapy Subjects receive investigational drug ( include placebo ) within 30 day Visit 1 Use treatment MDD within 7 day Visit 1 ( 14 day fluoxetine ) study study medication Use antidepressant , anxiolytic , psychoactive drug within 14 day Visit 1 study Concomitant use antibiotic penicillin class ( reduction potential additive synergistic hepatotoxicity ) A positive urine drug screen Elevation AST and/or ALT &gt; 3 time upper limit normal ( ULN ) Diabetic subject HbAlc â‰¥ 12 % Any abnormal screening laboratory value judge clinically significant Investigator Previous nonresponse hypersensitivity two trial antidepressant medication give adequate dos duration treatment symptom present current illness Subjects know hypersensitivity antibiotic penicillin class Subjects illiterate unable understand questionnaire Subjects , opinion investigator , would noncompliant visit schedule study procedure Subjects pose potential harm others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Major Depressive Disorder ( MDD )</keyword>
	<keyword>Serdaxin</keyword>
	<keyword>Rexahn</keyword>
</DOC>